{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:24:22Z","timestamp":1778217862391,"version":"3.51.4"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>The approach to eosinophilia and mast cell disorders in the bone marrow is diverse and depends on multiple factors including access to ancillary testing, resources to support testing, type of practice setting (eg, community, remote, tertiary care center or specialized referral center for these disorders) and whether there are options for clinical trial enrollment. That said, while there are some basic principles to the workup that we can all likely agree upon, individual practice habits will need to be tailored to suit an individual setting. As such, the approach presented in this manuscript is meant to serve as a practical guide and not as dogma per se. Importantly, an in-depth discussion of individual diseases and International Consensus Classification diagnostic criteria will not be covered, as the main focus of this article is the approach to these disorders. The reader is referred to a comprehensive discussion of these diseases and diagnostic criteria in several excellent articles. While there are clear areas of overlap between eosinophilia and mast cell conditions (eg, systemic mastocytosis associated with eosinophilia, myeloid neoplasm with eosinophilia, and tyrosine kinase rearrangements), it is the authors\u2019 opinion that it is perhaps easier to navigate these entities separately (eg, eosinophilia as one broad topic and mast cell conditions as another) and to recognize the settings in which overlap may exist and what testing might be considered. Eosinophilia and mast cell conditions will be discussed separately supplemented by generous use of figures and tables to highlight key points.<\/jats:p>","DOI":"10.1097\/pap.0000000000000486","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T05:15:30Z","timestamp":1743311730000},"page":"259-271","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["An Approach to the Bone Marrow Workup and Diagnosis of Eosinophilia and Mast Cell Disorders"],"prefix":"10.1097","volume":"32","author":[{"given":"Kaaren K.","family":"Reichard","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Utah, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"R1-20250606","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"R2-20250606","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00428-022-03423-3","article-title":"The international consensus classification of mastocytosis and related entities","volume":"482","author":"Leguit","year":"2023","journal-title":"Virchows Arch"},{"key":"R3-20250606","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ajh.26966","article-title":"The international consensus classification of eosinophilic disorders and systemic mastocytosis","volume":"98","author":"Wang","year":"2023","journal-title":"Am J Hematol"},{"issue":"2D","key":"R4-20250606","doi-asserted-by":"crossref","first-page":"e240030","DOI":"10.6004\/jnccn.2024.0030","article-title":"NCCN Guidelines\u00ae Insights: systemic mastocytosis, version 3.2024","volume":"22","author":"Gotlib","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-20250606","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ajcp\/aqae047","article-title":"How I diagnose systemic mastocytosis","volume":"162","author":"Rets","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"R6-20250606","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"R7-20250606","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev-pathmechdis-031521-042618","article-title":"New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy","volume":"18","author":"Valent","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"R8-20250606","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global classification of mast cell activation disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R9-20250606","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.3390\/ijms222011270","article-title":"Mastocytosis and mast cell activation disorders: clearing the air","volume":"22","author":"Jackson","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R10-20250606","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ACI.0000000000000849","article-title":"Hereditary alpha-tryptasemia","volume":"22","author":"Bonadonna","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R11-20250606","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.anai.2021.06.019","article-title":"Inherited and acquired determinants of serum tryptase levels in humans","volume":"127","author":"Lyons","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R12-20250606","first-page":"00907","article-title":"The normal range of baseline tryptase should be 1 to 15 ng\/mL and covers healthy individuals with H\u03b1T","volume":"S2213-2198","author":"Valent","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R13-20250606","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R14-20250606","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"R15-20250606","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.jaip.2023.05.012","article-title":"Disease spectrum of anaphylaxis disorders","volume":"11","author":"Gonz\u00e1lez de Olano","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R16-20250606","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: Proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R17-20250606","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"R18-20250606","doi-asserted-by":"crossref","first-page":"AB204","DOI":"10.1016\/j.jaci.2022.12.635","article-title":"Efficacy and safety of avapritinib in indolent systemic mastocytosis (ISM): results from the double blinded placebo-controlled PIONEER study","volume":"151","author":"Castells","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R19-20250606","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"key":"R20-20250606","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1309\/CX45R79PCU9HCV6V","article-title":"Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia","volume":"124","author":"Krokowski","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"R21-20250606","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1309\/AJCPSGQ71GJQQACL","article-title":"Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis","volume":"144","author":"Reichard","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"R22-20250606","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/bloodadvances.2023009826","article-title":"Challenges in applying diagnostic criteria for systemic mastocytosis","volume":"7","author":"Boggs","year":"2023","journal-title":"Blood Adv"},{"key":"R23-20250606","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.jaip.2021.12.031","article-title":"Elevated basal serum tryptase: disease distribution and variability in a regional health system","volume":"10","author":"Waters","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R24-20250606","doi-asserted-by":"crossref","first-page":"e12174","DOI":"10.1002\/clt2.12174","article-title":"Detection of clonal mast cell disease in wasp venom allergic patients with normal tryptase","volume":"12","author":"Onnes","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"R25-20250606","first-page":"100094","article-title":"Hereditary alpha-tryptasemia modifies clinical phenotypes among individuals with congenital hypermobility disorders","volume":"3","author":"Vazquez","year":"2022","journal-title":"HGG Adv"},{"key":"R26-20250606","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"R27-20250606","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1016\/j.jaip.2020.05.057","article-title":"Hereditary alpha-tryptasemia: UK prevalence and variability in disease expression","volume":"8","author":"Robey","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R28-20250606","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/bloodadvances.2022007936","article-title":"Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms","volume":"7","author":"Chovanec","year":"2023","journal-title":"Blood Adv"},{"key":"R29-20250606","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2022.09.038","article-title":"Disease correlates and clinical relevance of hereditary \u03b1-tryptasemia in patients with systemic mastocytosis","volume":"151","author":"Sordi","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20250606","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2023.08.015","article-title":"Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes","volume":"153","author":"Polivka","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R31-20250606","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jaci.2020.11.017","article-title":"Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology","volume":"147","author":"Giannetti","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R32-20250606","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.6004\/jnccn.2020.0042","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Gerds","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R33-20250606","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","article-title":"Eosinophilia: secondary, clonal and idiopathic","volume":"133","author":"Tefferi","year":"2006","journal-title":"Br J Haematol"},{"key":"R34-20250606","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00428-022-03402-8","article-title":"Updates on eosinophilic disorders","volume":"482","author":"Tzankov","year":"2023","journal-title":"Virchows Arch"},{"key":"R35-20250606","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R36-20250606","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"R37-20250606","doi-asserted-by":"crossref","first-page":"100809","DOI":"10.1016\/j.blre.2021.100809","article-title":"Hypereosinophilic syndromes\u2014an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment","volume":"49","author":"Helbig","year":"2021","journal-title":"Blood Rev"},{"key":"R38-20250606","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ajcp\/aqy064","article-title":"A test utilization approach to the diagnostic workup of isolated eosinophilia in otherwise morphologically unremarkable bone marrow: a single institutional experience","volume":"150","author":"Fang","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"R39-20250606","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/bjh.14488","article-title":"Guideline for the investigation and management of eosinophilia","volume":"176","author":"Butt","year":"2017","journal-title":"Br J Haematol"},{"key":"R40-20250606","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Shomali","year":"2024","journal-title":"Am J Hematol"},{"key":"R41-20250606","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000489341","article-title":"The Diagnostic Work-up of hypereosinophilia","volume":"86","author":"Wang","year":"2019","journal-title":"Pathobiology"},{"key":"R42-20250606","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"key":"R43-20250606","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"key":"R44-20250606","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1002\/ajh.25811","article-title":"WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): a contemporary series from the Mayo Clinic","volume":"95","author":"Morsia","year":"2020","journal-title":"Am J Hematol"},{"key":"R45-20250606","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","article-title":"Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"}],"container-title":["Advances in Anatomic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAP.0000000000000486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T10:00:39Z","timestamp":1749204039000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAP.0000000000000486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pap.0000000000000486","relation":{},"ISSN":["1072-4109","1533-4031"],"issn-type":[{"value":"1072-4109","type":"print"},{"value":"1533-4031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}